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Background: Cardiovascular disease is the leading cause of death throughout the world, with the majority of
deaths occurring in low- andmiddle-income countries. Despite clear evidence for the beneﬁts of blood pressure
reduction and availability of safe and low-cost medications, most individuals are either unaware of their condi-
tion or not adequately treated.
Objective: The primary objective of this study is to evaluate whether a community-based, multifaceted intervention
package primarily provided by nonphysician health workers can improve long-term cardiovascular risk in people
with hypertension by addressing identiﬁed barriers at the patient, health care provider, and health system levels.
Methods/design: HOPE-4 is a community-based, parallel-group, cluster randomized controlled trial involving 30
communities (1,376 participants) in Colombia and Malaysia. Participants ≥50 years old and with newly diagnosed
or poorly controlled hypertension were included. Communities were randomized to usual care or to amultifaceted
intervention package that entails (1) detection, treatment, and control of cardiovascular risk factors by nonphysician
health workers in the community, who use tablet-based simpliﬁed management algorithms, decision support, and
counseling programs; (2) free dispensation of combination antihypertensive and cholesterol-loweringmedications,
supervised by local physicians; and (3) support from a participant-nominated treatment supporter (either a friend
or familymember). The primary outcome is the change in Framingham Risk Score after 12months between the in-
tervention and control communities. Secondary outcomes including change in blood pressure, lipid levels, and
Interheart Risk Score will be evaluated.
Signiﬁcance: If successful, the study could serve as a model to develop low-cost, effective, and scalable strategies to
reduce cardiovascular risk in people with hypertension.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
Cardiovascular disease (CVD) is the major cause of mortality and
morbidity globally and affects half of all individuals over their lifetimes.1
Despite large reductions in age-adjusted mortality in many high-
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income countries (HICs), rates are now increasing in many low- and
middle-income countries (LMICs).2 In 2015, N75% of noncommunicable
disease deaths occurred in LMICs, with CVD as the leading cause (17.7
million deaths, or 45% of all noncommunicable disease deaths).3
Smoking, hyperlipidemia, hypertension, and diabetes account for 80%
of the population attributable risk for CVD, with hypertension fast be-
coming themain driver of CVD.4 Early detection of thesemodiﬁable car-
diovascular (CV) risk factors followed by initiation of and adherence to
existing evidence-based CV medications and lifestyle modiﬁcations can
substantially reduce CVD risk.5, 6
The Heart Outcomes Prevention and Evaluation 4 (HOPE-4)
community-based program in Malaysia and Colombia was informed
by an extensive analysis which included a systematic review of barriers
to effective hypertension management coupled with 2 in-depth mixed-
methods situation analyses in each country.7-9 These identiﬁed context-
speciﬁc factors, such as traditional health beliefs in Malaysia and frag-
mentation of provision of care in Colombia, and informed development
of a contextually appropriatemultifaceted intervention package for CVD
prevention in each country. We are testing this intervention package in
a community-based, parallel-group, cluster randomized controlled trial.
Substantial gaps in the detection, treatment, and control of CVD risk
factors occur globally, especially in LMICs.10-14 Barriers to CVD preven-
tion occur at 3 levels: patient, health care provider, and health system
levels (Table I).7, 8, 15-17 To overcome barriers at all these levels, we
have integrated the following 3 complementary approaches: (1) task-
shifting to teams of nonphysician health workers (NPHWs), supported
by mobile health (mhealth) tablets for decision support counseling
and data collection; (2) combination antihypertensive (anti-HT) and
cholesterol-lowering medications provided to eligible participants;
and (3) involvement of participant-nominated treatment supporters
to optimize long-term adherence to medications and healthy lifestyle.
I. Task-shifting, supported by tablet-operated, mhealth systems:
Detection of hypertension, documentation of risk factors, lifestyle
counseling, and reinforcement of adherence to prescribed medi-
cations can be done efﬁciently by community-based NPHWs.18
However, in most countries, prescribing drugs is only permitted
by licensed physicians. Therefore, theWorld Health Organization
(WHO) recommends a combined approach whereby NPHWs
identify individuals with hypertension/CVD risk and physicians
prescribe proven drugs following established guidelines. Such
an approach is particularly relevant in resource-challenged set-
tings where there are an inadequate number of physicians.19-24
Most screening guidelines for hypertension emphasize the need
for multiple readings of elevated blood pressure (BP) before initi-
ating treatment.25-28 However, these guidelines are based on ex-
periences in HICs with ample human and ﬁnancial resources and
have never been validated as being cost-effective or practical
from the patient perspective. The need to make multiple visits to
document whether or not BP is elevated is often a barrier to initi-
ation of anti-HT therapies.10 We hypothesize that simpliﬁed
Table I
Rationale and approach to intervention design in the HOPE-4 Program (adapted from
Schwalm et al 2016 Circulation article titled “Resource Effective Strategies to Prevent
and Treat Cardiovascular Disease”)43
Category of barrier Example of barrier Strategies in HOPE-4
Patient7
Availability, access, and
costs of medication
and health care
(external)
Lack of health insurance
(public or private)
(1) Free medication, (2)
NPHWs, (3) medication
delivery at the community
level
Knowledge (internal) Asymptomatic individuals
question need for ongoing
treatment
(1) NPHW-initiated
education/counseling, with
mhealth support; (2)
treatment supporters
Beliefs (internal) Alternative/traditional
medicine
NPHW-initiated education
to address beliefs that
impair acceptance of
evidence-based messages
Memory (internal) Affects adherence to
recommended therapies
and attendance to HCP
follow-up
NPHW-initiated visits with
participant (at least 6 total
visits in 12 m), (2)
treatment supporters to
promote and encourage
adherence
Adverse effects of
medications
(internal)
Real or perceived (myalgia,
cough, etc)
(1) NPHW assessment,
scheduling of
HCP-participant
appointment if necessary,
and education; (2) use of
low-dose combination
medications to minimize
adverse effects
Health care provider7, 41
Knowledge Familiarity and awareness
of management options
and guidelines
HOPE-4 simpliﬁed
treatment algorithm using
evidence-based
recommendations
Attitudes Lack of agreement on
guidelines, expectations,
self-efﬁcacy, motivation,
and treatment inertia
(1) Simpliﬁed algorithms,
informed by
evidence-based
recommendations,
packaged into a treatment
manual; (2) participant
risk and treatment
recommendations
suggested by NPHWs, with
mhealth support
Behavior External or environmental
factors limiting
management (time,
resources, reimbursement)
Task-shifting
responsibilities to NPHWs,
with mhealth support
Health system/policy42
Health care ﬁnancing
system
Low priority in national
budgets: competing
political agendas (military,
other medical conditions
such as HIV, etc); limited
universal health care
coverage
Partner with national
health care leaders in
Colombia and Malaysia
Medical products and
technologies
Lacking infrastructures for
stocking pharmacies with
evidence-based generic
medications; poor
affordability of essential
medications, even when
they are generic
Combination of purchased
and locally donated
combination CV
medications stocked and
provided to participants
Leadership/governance Low priority for CVD
prevention: lack of
effective screening
programs, smoking
cessation programs, safe
environments for exercise,
high costs for healthy
foods, lack of physical
activity
(1) Simpliﬁed treatment
and management
algorithms, with mhealth
support. This includes
simple and achievable
recommendations for
lifestyle changes. (2)
Treatment supporters add
layer of support
Health workforce Limited number of
adequately trained
Task-shifting
responsibilities to NPHWs
Table I (continued)
Category of barrier Example of barrier Strategies in HOPE-4
physicians and health care
professionals
supported by mhealth
technology
Health information
system and research
Limited health system
infrastructures to ensure
monitoring of health
determinants, performance
and health status
mhealth tablets provide
data management support
Service delivery Efﬁcient delivery of
effective and safe
interventions
Task-shifting of
responsibilities to NPHWs
at the community level,
with mhealth support and
HCP supervision
HCP, Health care provider.
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approaches to initiate anti-HT drugs with only 1 or 2 BP measure-
ments while simultaneously taking measures to reduce lipids and
modify other risk factors could reduce the risk of CVD in those at
high risk. Such approaches can now beneﬁt from advances in com-
puterized decision support systems.29-33 Thus, we integrated these
algorithms into the HOPE-4 tablet-based mhealth systems.
II. Use of free combination of anti-HT and cholesterol-lowering
medications:
Because no single drug reduces BP sufﬁciently in most people
with hypertension, BP control is better achieved using combina-
tions of low doses of anti-HT agents, an approach endorsed by
both European and US guidelines.27, 34 Given recent evidence
supporting the use of statins in thosewith hypertension, regard-
less of lipid status, this medication is also recommended for eli-
gible participants.35-38 High medication cost and limited
availability have been identiﬁed as a barrier to effective hyper-
tensionmanagement.39 Consequently, theHOPE-4 programpro-
vided these drugs at no cost in each country.
III. Treatment supporters:
Experience with HIV treatment has demonstrated that involve-
ment of uncompensated, participant-nominated friends or fam-
ily signiﬁcantly improved treatment adherence and reduced
mortality.40 Given similarities across chronic disease manage-
ment strategies, involving treatment supporters may also be an
effective approach to CVD management.
Research methods
Objectives
The goal of the HOPE-4 study is to evaluate an evidence-based, con-
textually appropriate program for CVD risk assessment, treatment, and
control involving the 3 elements set out above.
Study design
Using a parallel-group, cluster randomized controlled trial design, 30
communities have been randomized to usual care or to participate in an
intensive CVD risk detection and management program supported by
NPHWs for 12 months. Participants, NPHWs and local investigators
will not be blinded to the study group. Data collectedwill be transferred
to the Population Health Research Institute (PHRI) directly from the
tablets for analysis. This protocol is registered on www.clinicaltrials.
gov (identiﬁer NCT01826019).
Study population
Selection of communities
The study coordinating center and the national leaders in each country
have collaborated to develop country-speciﬁc deﬁnitions for urban and
rural communities and to identify the households to be screened within
each community. Use of a Community Characteristic Checklist (Table II)
to capture community demographics and health care facilities information
formalized the community selectionprocess and facilitated reporting that is
in linewith the Consolidated Standards of Reporting Trials guidelines.44 Es-
sentially, the communities were selected to minimize the risk of contami-
nation between clusters (ie, participants from one community are not
likely to visit the health care center in another community). This trial has
randomized 30 urban and rural communities in Colombia (registration
site: FOSCAL) and Malaysia (registration site: Universiti Teknologi MARA).
Participant selection
Screening to identify eligible participants involved a combination of
household sampling and the use of community outreach centers or
events based within public spaces, as appropriate to the region. For
this screening, medical clinics (ie, primary care physician ofﬁces or hy-
pertension clinics) were purposely avoided. Participants were consid-
ered eligible if they were ≥50 years old with at least ONE of the
following criteria:
1. Systolic blood pressure (SBP) ≥160 mm Hgwas recorded at 1 visit;
2. SBP 140-159mmHgwas recorded in 1 visit AND participant reported
amedical diagnosis of hypertensionorwas taking anti-HTmedication;
3. SBP ≥130 mm Hg was recorded in 1 visit AND participant reported a
medical diagnosis of diabetes or was taking medication for diabetes;
4. Participants did not meet criteria 1-3, but SBP 140-159mmHgwas
recorded on 2 separate visits at least 24 hours apart.
Participants were considered ineligible for this study if they (1) re-
fused to consent, (2) were concurrently participating in any other
study or heart health program that would compromise the protocol of
HOPE-4, (3) had severe comorbid condition with life expectancy b1
year, or (4) had other serious condition(s) or factors likely to interfere
with study participation or with their ability to complete the trial (see
Figure 1 for the enrollment process).
Table II
Community characteristics by country and urban or rural settings
Malaysia Colombia
Characteristics
Rural
8 clusters; n=341
Urban
7 clusters; n=275
Rural
6 clusters; n=307
Urban
9 clusters; n=453
Mean distance (km) between community
and coordination center
103.2
(SD 64.6)
35.2
(SD 23.2)
98.8
(SD 121.8)
42.8
(SD 51.6)
Mean population (n) 12,873.5
(SD 9778.5)
197,451
(SD 156,921.7)
22,188.5
(SD 15,622.1)
12,087.9
(SD 15,192.9)
Male (%) 51.4 53.2 51.7 49.1
Age ≥50 (%) 25.6 21.1 26.0 27.8
Storage of medication Locally stored Locally stored Centrally stored Centrally stored
Mean no. of government or
private clinics (n)
4.8
(SD 2.4)
19.0
(SD 7.7)
1.2
(SD 1.0)
2.7
(SD 3.9)
Mean no. of hospitals (n) 1.1
(SD 0.4)
3.3
(SD 1.6)
0.8
(SD 0.4)
0.9
(SD 0.3)
Mean no. of tertiary care
centers (n)
0 0.6
(SD 0.8)
0.2
(SD 0.4)
0.7
(SD 0.5)
Mean no. of specialist centers (n) 0 0.3
(SD 0.5)
0
(SD 0)
0
(SD 0)
Primary settings for recruitment
data collection
99% from public
community centers;
1% from private
households
75% from public
community centers;
25% from private
households
100% from private
households
100% from private
households
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Informed consent
All participants ≥50 years old were asked to sign a short informed
screening consent formprior to completion ofmedical history screening
questions and BP assessment to determine study eligibility (Appendix
A). Participants who wish to participate in the trial must sign an in-
formed enrollment consent form (Appendix B). This consent can occur
at the same visit immediately after the completion of initial screening
or in the targeted 14-day follow-up period after initial screening, de-
pending on the results of screening and number of visits required to es-
tablish eligibility.
Randomization
Following screening and complete participant enrollment within a
given community, communities were randomized 1:1 by a computer-
generated, central (PHRI) randomization system to either the interven-
tion or control group. Each community was randomized after the entire
community was screened to avoid selection bias. This strategy limits
biases regarding which participants would be included in the trial be-
fore randomization within each community. All participants within
the deﬁned community will receive the allocated treatment. Stratiﬁed
randomization was ﬁrst by country and then by rural or urban location
of the community. Rural/urban stratiﬁcation was undertaken, as there
are marked differences in the use of secondary preventative medica-
tions and in hypertension control between these settings as docu-
mented in the Prospective Urban and Rural Epidemiological (PURE)
study, which is being undertaken in both countries.10, 14
Intervention components
This cluster randomized controlled trial involves a complex inter-
vention consisting of 3 core elements (Figure 2) provided as a package:
(1) task-shifting to NPHWs, (2) dispensing combination anti-HT and
cholesterol-lowering medications and reinforcing adherence, and
(3) involvement of participant-nominated treatment supporters to en-
courage adherence, adapted to the local context.
Task-shifting
A curriculum for training of NPHWs was jointly developed by PHRI
and theWHOwith 9modules of instructions.23, 45 In this 2-week curric-
ulum, NPHWswere trained on a variety of topics ranging from common
CV health knowledge to CV risk detection, treatment, and lifestyle man-
agement. NPHWs were also trained to counsel both the study partici-
pants and their nominated treatment supporters on the beneﬁts of
adherence to medication and adoption of healthy living (eg, diet,
exercise, and smoking cessation). These are reiterated with each
NPHW-participant contact. Local primary health care physicianswill re-
view decisions made by the NPHW, as well as initiate simpliﬁed algo-
rithms for medication dispensation where appropriate.
To further promote task-shifting of responsibilities to NPHWs, tab-
lets with HOPE-4 software were developed and provided to all
NPHWs. To support decisions, counseling, and data collection, tablets
were programmed with simpliﬁed clinical algorithms, NPHW counsel-
ing prompts, and study management instructions, all based on the
study protocol and the curriculum developed for the NPHWs.
The tablets were validated and tested before distribution.46 Using
branching logic and decision trees, the tablets speciﬁcally provide
NPHWs with (1) step-by-step screening assessments; (2) secure elec-
tronic data capture and transfer; (3) progress indicators on the status
of each participant, describing completeness of data collection; and
(4) real-time decision support and feedback for both participant guid-
ance and data validation. Similar to other computer decision-support
systems, the tablet offers the ability to use preprogrammed clinical
knowledge so that recommendations can be made once characteristics
of the participant are entered, based on expert physician knowledge,
guidelines, and the standardized WHO/package of essential
noncommunicable disease protocols.47
Administration of study medications
Study-associated medications are obtained from a local manufac-
turerwithin each country. Although the precise formulations used differ
in each country, the recommended CV medications include single-pill
combinations of anti-HT medications (both low- and high-dose op-
tions) and a cholesterol-lowering agent (statin) (Table III). Initiation
of medication options from Table III is based on recommendations
from the NPHW, but the ultimate decision is left to the discretion of
the participating local physician, depending on (1) the communities’
medication availability and the participant’s (2) BP, (3) risk proﬁle,
and (4) allergies/medication intolerances. Eligible participants already
taking CV medication(s) are reviewed by the NPHW and supervising
physician for potential transition (if appropriate) to the study-
associated medications in accordance with local policy and guidelines,
but this is not mandatory. Participating NPHWs and physicians have
been provided with suggested medication management algorithms tai-
lored to available study-associated medications (Figure 3).
Safety reporting
Safety reportingwill be customized for each region, country, and the
regulatory status and type of study-associatedmedication provided and
used, as appropriate, and as required by regulatory authorities within
participating countries. If study-associated medication (ie, medication
obtained centrally and provided free of charge to participating interven-
tion communities) is not provided to a given region or country as part of
HOPE-4, it is expected that no medication-related safety reporting will
be required, in accordance with local regulations. It is also expected
that medication-related safety reportingwill not be required for control
communities, in accordance with local regulations. Any participants
experiencing adverse effects or uncontrolledHTwithin the intervention
group will be managed by study physicians as per local policy and
guidelines. Participants who develop intolerable adverse effects to a
component of any study-associated medication may be transitioned to
amore suitable study-associatedmedication or to its individual compo-
nents or other suitable medications, if available, in accordance with
local policy and guidelines.
These algorithms will prioritize the use of combined anti-HT and
cholesterol-lowering medications in tolerant participants. Any partici-
pant experiencing adverse effects or uncontrolled hypertension will
be managed by local health care providers as per local policy and
guidelines.
Figure 1. Flowchart of the participant enrollment process.
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Control
No structured interventions will be used in the control arm. During
screening, control participants will be provided with existing govern-
ment/health system CVD literature and be advised to see their usual
provider for care, as appropriate. Treatments prescribed are recorded
in each participant.
Study visits and data collection
Study visits anddata collectionwill be conducted by trainedNPHWs,
who will travel to the participants’ homes or community outreach cen-
ters within preselected communities (see Table II for the Community
Characteristic Checklist used to select communities). At
prerandomization screening, NPHWs will assess each consenting indi-
vidual aged 50 years or older and collect physical measurements to de-
termine study eligibility. At 6 and 12 months postrandomization in
intervention and control communities, NPHWswill repeat study assess-
ment procedures to ensure that any changes to the components of Fra-
mingham Risk Score (FRS) are captured. Bloodwork will be collected in
participants at baseline and 12 months (low-density lipoprotein (LDL),
high-density lipoprotein (HDL), triglycerides, total cholesterol, and glu-
cose). Blood pressures are taken at each visit using the WHO STEPS
Protocol.48
Communities randomized to interventionwill have additional visits,
which include a baseline visit (time-0 visit; a participant-NPHW visit,
and a participant-physician visit) at 1 and3months postbaseline. An ad-
ditional telephone call will bemade to intervention participants at 10 or
11 months to conﬁrm availability for the upcoming 12-month visit.
Communities randomized to control will have no additional visits—
only a telephone call at 3months and at 10 or 11months to conﬁrm up-
coming visits with the NPHW.
Data will usually be collected using tablets; however, NPHWs can
choose to capture data on paper forms for later entry if necessary de-
pending on the participant and setting.
Figure 4 shows a summary of the NPHWmanagement responsibili-
ties in intervention and control groups.
Outcomes
The complexHOPE-4 intervention is designed to address CVD risk by
improving BP and lipid control and promoting smoking cessation as
well as other lifestyle modiﬁcations. Therefore, a validated risk score
assessing the major modiﬁable CVD risk factors is required to properly
evaluate the effect of HOPE-4 interventions. The FRS is a tool to estimate
the risk of CVD development based on age, sex, BP, use of anti-HT
medication, blood cholesterol, smoking, and diabetes. The FRS was ini-
tially developed in white Americans but has subsequently been widely
validated in different ethnic groups.49, 50 The primary objective of
HOPE-4 is to evaluate whether or not the intervention can substantially
improve the FRS at 1 year. Given the potential for detection bias (in-
creased screening in the intervention group), the development of a
new diagnosis of diabetes after the initial screening assessment will
not factor into the FRS calculation at 12 months. We expect that
HOPE-4 will also have an 80% power to detect small changes in BP
(≥2.9 mm Hg) and LDL cholesterol (≥0.67 mmol/L), as secondary
outcomes.
Primary outcome
The primary outcome is the mean difference in FRS change from
baseline to 12months between the intervention and control communi-
ties. The FRSwill be calculated using lipid measurements, but if they are
missing, a nonlaboratory FRS validated formulawill be used.51 Although
the HOPE-4 study initially planned to assess change in SBP as the pri-
mary outcome, it was felt that this outcome did not reﬂect themultifac-
eted nature of the intervention. This study is well powered for both FRS
and SBP as outcomes of interest.
Secondary outcomes
The secondary outcomes are (1) change in SBP between the inter-
vention and control communities at 6 and 12 months; (2) change in
LDL, HDL, total cholesterol, triglycerides, and glucose levels at 12
months; (3) proportion of participants with well-controlled BP at 6
and 12 months (SBP b 140 mm Hg); (4) change in smoking status at 6
and 12 months.
Tertiary outcomes
The tertiary outcomes are (1) change in Interheart Risk Score at 6
and 12 months and Cholesterol Modiﬁable Risk Score at 12 months,
(2) change in lifestyle modiﬁcation (exercise and diet-based on compo-
nents of the Interheart Risk Score), (3) proportion of participants receiv-
ing 2 or more anti-HT and a statin at 6 and 12 months, (4) medication
adherence measures at 6 and 12 months, (5) country-speciﬁc process
outcomes at 6 and 12 months involved in the intervention, and
(6) health economic analyses.
Safety outcomes
The safety outcomes are clinical events (eg, death, CVD develop-
ment, hospitalizations) at 6 and 12months. However, given themodest
sample size and relatively short duration of the intervention, the study
will not have high power to detect differences in these outcomes.
Figure 2. Intervention components of HOPE-4.
61J.-D.R. Schwalm et al. / American Heart Journal 203 (2018) 57–66
Statistical considerations
Sample size
Sample size calculations used data from participants enrolled in the
PURE study from Malaysia and Colombia.52, 53 HOPE-4 participants are
expected to be similar to the PURE study population. Among the 2,832
PURE participants from Malaysia and Colombia that met HOPE-4 eligi-
bility, the mean baseline FRS score was 24.7% (SD 15). The mean SBP
is 160 (SD 19) and LDL cholesterol is 3.58 mmol/L (SD 1.09). The com-
munity intraclass correlation coefﬁcients (ICCs) for FRS, SBP, and LDL
cholesterol were 0.052, 0.017, and 0.11, respectively. We set a sample
size of 1,200 across the 2 groups (30 clusters with 40 each in size; 600
in the intervention and 600 in the control group). Based on these as-
sumptions, we will have 80% power to detect at least 3.0% absolute
FRS percentage points difference in FRS between intervention and con-
trol group. Similarly, for our secondary outcomes, we will have 80%
power to detect a 2.9–mmHgdifference in BP and a 0.32-mmol/L differ-
ence in LDL between these 2 groups (Tables IV and V).
Analyses
Analysis and reporting of results will follow the Consolidated Stan-
dards of Reporting Trials guidelines for cluster randomized controlled
trials.54 The analysis of both primary and secondary outcomes will ac-
count for the clustering effect using mixed-effects model with commu-
nity as a random effect. We will use multiple imputation strategies
based on the baseline characteristics to take into account missing data
on all outcomes. We will undertake an intention-to-treat analysis.55
All statistical tests will be performed using 2-sided tests at the .05
level of signiﬁcance. Final results will be expressed as a mean along
with 2-sided 95% CIs and P values. The consistency of treatment effects
on the primary outcome will be explored in predeﬁned subgroups, in-
cluding socioeconomic status, education, gender, country, urban/rural
community, and young/old, and by risk score tertile. Tests for interac-
tions of subgroupswith the interventionwill be performed by including
an interaction term in the model. These subgroup analyses will not be
adjusted for multiple testing because the analyses are exploratory.
We will perform the following sensitivity analyses for the primary
outcome, altering the model for analysis of cluster randomized con-
trolled trials.56 First, we will use a generalized estimating equation, as-
suming an exchangeable correlation structure within each
community.57 We will also use:(1) random-effects patient-level analy-
sis methods and cluster-level (ie, random- and ﬁxed-effects meta-
analytic) methods to assess the robustness of the results; (2) per-
protocol analysis; and (3) IMPACT analysis approach to describe the de-
gree to which each component contributed to the reduction in clinical
outcomes.58 Although the primary analysis will be a direct estimate of
the intervention package, we can “deconstruct” the contributions of
each component.59 We will also relate the individual components of
the intervention to the change in risk score, and this will allow us to
identify the components which are most effective. This information
can then be used to develop variations of the interventions, depending
on the context.
Data management, quality, and security
The study will use a mixture of paper and electronic case report
forms (CRFs), as appropriate for each community, region, country, and
study process. Study personnel will complete either paper CRFs or elec-
tronic CRFs using an encrypted, password-protected, portable tablet de-
vice or computer securely connected to PHRI’s data management
platforms via the Internet.With prior consent of the participants, source
documentation supporting the trial information reported on the CRFs or
electronic CRFs (including verbal narratives of outcome events, medical
records or other documents provided by participants, and consent
forms,where feasible)will be photographed or recordedby the portable
tablet devices during household and clinic visits and securely transmit-
ted to the PHRI data center for event adjudication purposes aswell as for
central monitoring of the study conduct. Paper CRFs will be collected
and reviewed by the National Project Ofﬁce personnel, with data
being submitted to the centralized PHRI systemby fax or through secure
electronic submission to PHRI’s data management platforms.
Data management in HOPE-4 will include the following procedures:
(1) National Project Ofﬁce personnel and community-based teams will
undergo training sessions prior to study commencement to ensure con-
sistency in project procedures including data collection and reporting;
(2) National Project Ofﬁces will have a detailed Manual of Operations
that will outline each step of the protocol and will be able to communi-
catewith theHOPE-4 Project Ofﬁce via email to resolve any problems or
questions that arise; (3) the PHRI Project Ofﬁce personnel will review
detailed monthly reports on screening, enrollment, patient follow-up,
completeness of data collection, and overall study event rates; (4) the
centralized PHRI databases will include internal validity and range
checks to identify errors or omissions and notify theNational Project Of-
ﬁces of any issues; and (5) PHRI personnel will visit National Project Of-
ﬁces (and possibly community-based clinics) for monitoring purposes,
as required.
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Health economic evaluation
Wehypothesize that this intervention packagewill improve risk fac-
tor control signiﬁcantly. Although this study is not designed to observe
signiﬁcant reductions in clinical events, wewill model the impact of the
differences in risk factors to project the differences in clinical events. It is
expected that the long-term clinical beneﬁts of this intervention would
be at least cost-neutral and potentially cost-saving when compared to
current practice. We will collect data that will allow us to determine
(1) the cost of the suggested program (ie, intervention package) and
Table III
Combination anti-HT study medications dispensed in Malaysia and Colombia
Malaysia⁎ Colombia⁎
Anti-HT
medications
Doses Anti-HT medications Doses
Options: low-dose combinations Options: low-dose combinations
1 Perindopril 4 mg 1 Amlodipine 5 mg
Indapamide 1.25 mg Valsartan 80 mg
2 Telmisartan 80 mg 2 Candesartan 16 mg
Amlodipine 5 mg Amlodipine 5 mg
Options: high-dose combinations Options: high-dose combinations
1 Telmisartan 80 mg 1 Amlodipine 10 mg
Amlodipine 10 mg Valsartan 160 mg
2 Amlodipine 5 mg 2 Amlodipine 5 mg
Valsartan 80 mg Valsartan 160 mg
3 Amlodipine 5 mg Hydrochlorothiazide 12.5 mg
Valsartan 160 mg 3 Candesartan 32 mg
Amlodipine 5 mg
⁎ Atorvastatin 20 mg or rosuvastatin 10 mg also provided to eligible participants.
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the cost of what is being provided currently for CVD assessment and
management in the communities studied (ie, control) and (2) the po-
tential for future cost-savings due to projected reduction in CVD events
stemming from the adoption of the program andmodeled over a 5-year
period based on changes in the FRS.
Process evaluation
Structured evaluations of newhealth initiatives are necessary topro-
vide evidence for practice and policy development.60, 61 Large-scale in-
vestigations of a complex intervention—such as HOPE-4—can be
complemented and informed by process evaluations conducted in par-
allel to themain study.60, 62 InHOPE-4, process evaluations of the role of
the NPHWs and treatment supporters, as well as a study of medication
adherence, will help inform CVD risk reduction program implementa-
tion strategies, post–study completion.
Ethical considerations
Before study initiation, the Institutional Review Board/Independent
Ethics Committee (IRB/IEC) of participating institutions and regulatory
authorities approved the HOPE-4 protocol. The IRB/IEC of participating
institutions approved the dispensation of study-associated medications
to the intervention group alone based on the following: (1) themedica-
tionswere locally available, (2) themedicationswere used per accepted
indications, and (3) themedicationswere prescribed by local physicians
as per current standards of care. The IRB/IEC also approved that no
study-associated medications were to be administered in the control
group for the following reasons: (1) the study screening process in the
control group already went above usual care by identifying participants
with CVD risk (ie, elevated blood pressure), (2) provided them with
locally available management literature, and (3) recommended they
seek assessment at a local health care facility.
Trial status
The HOPE-4 study has randomized 30 communities (1,376 partici-
pants) in Colombia and Malaysia (Table VI). All 30 communities will
complete 1-year follow-up by the end of 2018. Analysis of completed
follow-up data is expected to begin in the ﬁrst quarter of 2019. At the
end of the study, participants will be transitioned to continue current
or comparable medication therapy as is available in local communities
and will receive guidance from local care providers.
Initial plans for theHOPE-4 study included a CVD phase, with expan-
sion to 190 communities (9,500 participants), 6 years of follow-up, and
a difference in cardiovascular events as the primary outcome. Unfortu-
nately, funding limitations prevented expansion to this phase of the
HOPE-4 study.
Discussion
Hypertension is the commonest cause of CVD and themain driver of
CVD globally, but its control is poor in almost all countries.10 The HOPE-
4 study involves the integration and implementation of multiple
evidence-based strategies to overcome barriers to better hypertension
detection, treatment, and control, simultaneous with efforts to modify
lipids and other risk factors. If successful, this health system interven-
tion is scalable and sustainable and can be the basis for the development
of context-speciﬁc approaches in countries at different economic levels.
Although the study is taking place in 30 urban and rural communities in
Colombia andMalaysia, the rigorous cluster randomized controlled trial
Figure 3. Study statin and anti-HT medication algorithms for initiation.
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design and associated process evaluationswill allow for generalizability
of the results to a broader global population.
Limitations
Given the pragmatic design of this community-based cluster ran-
domized controlled trial, which builds on existing infrastructure within
participating countries, blinding is not feasible. Contamination will be
minimized, as only those communities randomized to the intervention
will have access to the counseling provided by NPHW, simpliﬁed
management algorithms, and the study-provided medications. In addi-
tion, communities have been chosen with adequate geographic separa-
tion from each other. Participants in the control group have had CVD
risk screening at baseline and have been provided with information
about local CV health programs and recommendations. Thismay reduce
the effect of the intervention, as control participants may modify their
behavior by seeking medical attention after knowing their BP was not
Figure 4. NPHW responsibilities in intervention and control groups. ISH, International Society of Hypertension; BMI, body mass index.
Table IV
Minimumdetectable differences inmean Framingham risk estimate between intervention
and control group at the end of 1-year follow-up (taking into account the effect of cluster-
ing and using analysis of covariance)
ICC
Minimum detectable FRS, %
SD of 15 SD of 20 SD of 25
0.05 3.0 4.0 5.0
0.07 3.4 4.9 5.6
Assuming a sample of size 1200 participants from 2 groups (15 clusters per group, 40 par-
ticipants per cluster) and a baseline mean (SD) risk of 24.7% (15) with a 2-sided test at 5%
label of signiﬁcance (estimates from the PURE study).
Table V
Detectable differences in mean BP and LDL estimate between intervention and control
group at the end of 1-year follow-up (taking into account the effect of clustering and using
analysis of covariance)
ICC
Power
Comparing mean BP (mm Hg) Comparing mean LDL (mmol/L)
80% 80%
0.1 5.5 0.320
0.05 4.3 0.243
0.01 2.9 0.167
Assuming a sample of size 1200 participants from 2 groups (15 clusters per group, 40 par-
ticipants per cluster) and a baseline mean (SD) SBP of 160 (19) with an ICC = 0.017 and
baseline mean (SD) LDL of 3.58 (1.09) with an ICC=0.11 (estimates from PURE study).
Two-sided test at 5% label of signiﬁcance.
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under control at the beginning of the study. This means that the
observed differences in risk factors between the active and control
groups are likely to be underestimates of the full effects of this
intervention strategy.
Signiﬁcance
In 2011, the United Nations adopted a global target of a 25% reduc-
tion in prematuremortality from CVD and other noncommunicable dis-
eases by 2025.63 The United Nations action plan designated 8 indicators
to measure progress, including improvements in (1) BP, (2) tobacco
cessation, (3) physical inactivity, (4) sodium intake, (5) alcohol con-
sumption, (6) diabetes and obesity rates, (7) access to drugs and CVD
risk prevention counseling, and (8) availability of basic technologies
and essential medicines.64 Similar elements are included in the Sustain-
able DevelopmentGoals. TheHOPE-4 program is designed to address all
8 componentswith a focus on BP and lipids. This low-cost strategy using
inexpensive generic medications, coupled with low-cost NPHWs sup-
ported by novelmhealth systems to reach and serve at-risk populations,
can tackle one of the largest contributors to the global disease burden
and potentially save millions of lives each year. Furthermore, this strat-
egy is applicable to bothHICs and LMICs so that, if successful, it can have
a signiﬁcant global impact and be incorporated into the health systems
of many different countries. The HOPE-4 program has similarities to the
approach taken in a variety of other successful health system strategies
dealingwith other conditions (eg, HIV, TB,malaria, immunizations) and
even to some extent the management of heart failure in HIC. Therefore,
given the simplicity and safety of the approach, the HOPE-4 program
has the potential to make a signiﬁcant impact on the burden of CVD.
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